Aluminum Nitride (AlN) Wafer
Market Analysis and Insights: Global and United States Aluminum Nitride (AlN) Wafer Market ... Read More
nsulin glargine, marketed under the names Lantus among others, is a long-acting basal insulin analogue, given once daily to help control the blood sugar level of those with diabetes. It consists of microcrystals that slowly release insulin, giving a long duration of action of 18 to 26 hours, with a "peakless" profile (according to the insulin glargine package insert).
Market Analysis and Insights: Global and United States Insulin Glargine Market
This report focuses on global and United States Insulin Glargine market, also covers the segmentation data of other regions in regional level and county level.
Due to the COVID-19 pandemic, the global Insulin Glargine market size is estimated to be worth US$ 6708 million in 2022 and is forecast to a readjusted size of US$ 8487.8 million by 2028 with a CAGR of 4.0% during the review period. Fully considering the economic change by this health crisis, by Type, Prefilled Injection accounting for % of the Insulin Glargine global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR in the post-COVID-19 period. While by Application, Type 1 Diabetes Treatment was the leading segment, accounting for over percent market share in 2021, and altered to an % CAGR throughout this forecast period.
Global Insulin Glargine key players include Sanofi, Eli Lilly, etc. Global top two manufacturers hold a share nearly 50%.
USA is the largest market, with a share over 60%, followed by China, and Europe, both have a share about 35 percent.
In terms of product, Pre-filled Syringe is the largest segment, with a share about 75%. And in terms of application, the largest application is Treat type2 diabetes, followed by Treat type1 diabetes.
Global Insulin Glargine Scope and Market Size
Insulin Glargine market is segmented by region (country), players, by Type and by Application. Players, stakeholders, and other participants in the global Insulin Glargine market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application for the period 2017-2028.
For United States market, this report focuses on the Insulin Glargine market size by players, by Type and by Application, for the period 2017-2028. The key players include the global and local players, which play important roles in United States.
Segment by Type
Prefilled Injection
Non-Prefilled Injection
Segment by Application
Type 1 Diabetes Treatment
Type 2 Diabetes Treatment
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Sanofi
Eli Lilly
Viatris
Gan&Lee Pharmaceuticals
Tonghua Dongbao Pharmaceutical
United Laboratories International
Market Analysis and Insights: Global and United States Aluminum Nitride (AlN) Wafer Market ... Read More
Military Armored Vehicles market is segmented by region (country), players, by Type and by Applic ... Read More
Hollow fibre (hollow fiber) configurations comprise one of the three main configurations for memb ... Read More